Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 8/20 | 0.73 |
| ▸ | LYN | P07948 | 1/20 | 0.63 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.63 |
| ▸ | BRAF | P15056 | 6/20 | 0.44 |
| ▸ | SCARB1 | Q8WTV0 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13797993 | 0.90 | MAPK14 (0.74) | MAPK14LYNMAPK9BRAFSCARB1 | |
| SCHEMBL13797938 | 0.89 | MAPK14 (0.73) | MAPK14LYNMAPK9BRAFSCARB1 | |
| SCHEMBL13359122 | 0.89 | MAPK14 (0.73) | MAPK14LYNMAPK9BRAFSCARB1 | |
| SCHEMBL13797943 | 0.88 | MAPK14 (0.72) | MAPK14LYNMAPK9BRAFSCARB1 | |
| SCHEMBL13810713 | 0.87 | MAPK14 (0.70) | MAPK14LYNMAPK9BRAFSCARB1 | |
| SCHEMBL13797996 | 0.86 | MAPK14 (0.69) | MAPK14LYNMAPK9BRAFSCARB1 | |
| SCHEMBL13797952 | 0.86 | MAPK14 (0.72) | MAPK14LYNMAPK9BRAFSCARB1 | |
| SCHEMBL13797955 | 0.86 | MAPK14 (0.64) | MAPK14LYNMAPK9BRAFSCARB1 | |
| SCHEMBL13359242 | 0.85 | MAPK14 (0.68) | MAPK14LYNMAPK9BRAFSCARB1 | |
| SCHEMBL13797936 | 0.85 | MAPK14 (0.68) | MAPK14LYNMAPK9BRAFSCARB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1497278-B1 | HETEROCYCLIC AMIDE DERIVATIVES AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (US) | 2010-05-26 | — | — | EP | disclosed |
| US-7550461-B2 | Benzofuran and benzothiophene compounds useful in treating cytokine mediated diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550461-B2 | Benzofuran and benzothiophene compounds useful in treating cytokine mediated diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550461-B2 | Benzofuran and benzothiophene compounds useful in treating cytokine mediated diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-20030225053-A1 | Compounds useful in treating cytokine mediated diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225053-A1 | Compounds useful in treating cytokine mediated diseases | IL6, IL1A, IL1B | MAPK14 2121/4885LYN 2917/4885MAPK9 1942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.